THE INVESTOR

메뉴열기
July 18, 2019

GemVax & KAEL recruits patients for Alzheimer’s therapy clinical trials

PUBLISHED : March 13, 2019 - 16:04

UPDATED : March 13, 2019 - 16:17

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

South Korean new drug developer GemVax & KAEL announced on March 13 that it has recruited 90 patients to conduct phase 2 clinical trials of its treatment for Alzheimer’s disease.

“Since the trials required patients with severe Alzheimer’s disease who must be accompanied by a guardian, recruiting was a difficult process,” CEO Song Hyoung-gon said in a statement. “We hope to see meaningful results attesting to the potential of GV1001 as an effective therapy.”




GV1001 is a synthetic peptide derived from human telomerase that was originally developed to fight cancer. The company found through previous clinical trials that GV1001 inhibits the build-up of amyloid beta and tau proteins, and can be used to treat Alzheimer’s disease.

Since it usually takes around six months to finish the phase 2 clinical trials, the company expects to evaluate the results by the year-end.

GemVax & KAEL is the only Korean Alzheimer’s disease treatment developer that actually has the likelihood of modifying the disease, according to the firm. Data provided by consulting firm GlobalData shows that Alzheimer’s disease treatment market in seven countries including the US, France, Germany, Italia, Spain, England and Japan, is expected grow to around 16 trillion won ($14.13 billion) by 2026.

By Song Seung-hyun(ssh@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
Publisher. Editor : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Yang Sung-jin
Title : The Investor|Date of registration : 2015.04.28
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0114|Business info
Gov’t registration No. Seoul 아04099
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.